Xenetic Biosciences Inc. (XBIO)
3.80
-0.12 (-3.06%)
At close: Mar 03, 2025, 11:04 AM
No 1D chart data available
| Bid | 3.79 |
| Market Cap | 5.86M |
| Revenue (ttm) | 2.52M |
| Net Income (ttm) | -4.08M |
| EPS (ttm) | -2.66 |
| PE Ratio (ttm) | -1.43 |
| Forward PE | -6.21 |
| Analyst | n/a |
| Ask | 3.85 |
| Volume | 1,892 |
| Avg. Volume (20D) | 9,413 |
| Open | 3.80 |
| Previous Close | 3.92 |
| Day's Range | 3.79 - 3.81 |
| 52-Week Range | 2.78 - 5.20 |
| Beta | 2.24 |
About XBIO
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor ...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 30, 2016
Employees 4
Stock Exchange NASDAQ
Ticker Symbol XBIO
Website https://www.xeneticbio.com
Next Earnings Release
Xenetic Biosciences Inc. is scheduled to release its earnings on Mar 20, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
